INMED PHARMACEUTICALS INC. (INM)

1.38USD +3.76% (+0.05)

Over 6M: +55.8%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

1 1.5
Mar Apr May Jun Jul Aug Sep

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q1 '22 — Free Cash Flow: -2.9M Q2 '22 — Cost of Revenue: 153.5K Q2 '22 — Free Cash Flow: -3.7M Q3 '22 — Cost of Revenue: 127.3K Q3 '22 — Free Cash Flow: -5.4M Q4 '22 — Cost of Revenue: 265K Q4 '22 — Free Cash Flow: -4M Q1 '23 — Cost of Revenue: 235K Q2 '23 — Cost of Revenue: 338.6K Q3 '23 — Cost of Revenue: 841.4K Q4 '23 — Cost of Revenue: 1.3M Q1 '24 — Cost of Revenue: 880.6K Q2 '24 — Cost of Revenue: 916.1K Q3 '24 — Cost of Revenue: 883.1K Q3 '24 — Free Cash Flow: -1.9M Q4 '24 — Cost of Revenue: 817K Q4 '24 — Free Cash Flow: -1M Q1 '25 — Cost of Revenue: 771.2K Q2 '25 — Cost of Revenue: 650.8K Q3 '25 — Cost of Revenue: 1.1M Q4 '25 — Cost of Revenue: 728.1K Q1 '26 — Cost of Revenue: 717K Q2 '26 — Cost of Revenue: 636K -4.5M -3M -1.5M 0 1.5M
Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Cost of Revenue Free Cash Flow

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

5.6
OE margin -167.9%
Accruals -11.5%
Gross margin 29.7%
FCF margin -165.5%
OCF margin -165.5%
Profit margin -188.8%
ROA -93.2%
ROE -123.5%
Capex / sales —
EBITDA margin —
OCF / EBIT —
Oper. margin —
ROCE —
ROIC —

2 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

10.0
EV/OE 0.083×
EV/GP -0.47×
EV/Sales -0.14×
P/B 0.66×
P/C 0.88×
FCF yield -163.1%
Div. yield —
EV/EBIT —
Fwd P/E —
P/E —
PEG —

1 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.7
ND/EBITDA -8.3
Cash runway 0.7 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 2.7×
F-score 4.5 pts
Cash / Debt —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

2.8
Sales CAGR 4Y +26.9%
Sales/sh Y/Y -63.6%
Sales Q/Q -26.2%
Shares change +156.3%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

2 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.